Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1994 2
1996 5
1997 3
1999 1
2000 2
2001 2
2004 3
2005 2
2006 1
2007 1
2008 1
2009 2
2010 2
2012 5
2013 2
2014 3
2015 2
2016 3
2017 7
2018 5
2019 1
2020 2
2021 4
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus.
Karnell JL, Wu Y, Mittereder N, Smith MA, Gunsior M, Yan L, Casey KA, Henault J, Riggs JM, Nicholson SM, Sanjuan MA, Vousden KA, Werth VP, Drappa J, Illei GG, Rees WA, Ratchford JN; VIB7734 Trial Investigators. Karnell JL, et al. Sci Transl Med. 2021 May 26;13(595):eabf8442. doi: 10.1126/scitranslmed.abf8442. Sci Transl Med. 2021. PMID: 34039741 Clinical Trial.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
Trypanosoma cruzi, organ transplant related.
Latzke AB, Fernández P, Chiurchiu C, De la Fuente JL, Caliva S, Bonisconti F, Caeiro JP. Latzke AB, et al. Among authors: de la fuente jl. IDCases. 2017 Sep 5;10:60. doi: 10.1016/j.idcr.2017.09.001. eCollection 2017. IDCases. 2017. PMID: 28948153 Free PMC article. No abstract available.
Characteristics of patients with fibromyalgia.
Padín Galea JM, Fernández-Aceñero MJ, de la Fuente JLM. Padín Galea JM, et al. Among authors: de la fuente jlm. Foot (Edinb). 2017 Aug;32:27-29. doi: 10.1016/j.foot.2017.04.001. Epub 2017 Apr 4. Foot (Edinb). 2017. PMID: 28668735
60 results